Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-high-dose Vitamin D Supplementation in HSCT Patients
NCT03759262Phase 1Completed
- Sponsor
- Children's Hospital Los Angeles
- Start
- Dec 2018
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vitamin d in graft-versus-host disease (GVHD), veno-occlusive disease (SOS), thrombotic microangiopathy (TMA) and 1 more, sponsored by Children's Hospital Los Angeles. Primary endpoints: Incidence of graft-versus-host disease, veno-occlusive disease, and thrombotic microangiopathy and Vitamin D sufficiency following Stoss dosing. Started Dec 2018; status: completed.
02
Drugs
vitamin d
03
Conditions
graft-versus-host disease (GVHD)veno-occlusive disease (SOS)thrombotic microangiopathy (TMA)Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on NCT03759262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759262.